Ishimori, Shingo
Ando, Takashi
Kikunaga, Kaori
Terano, Chikako
Sato, Mai
Komaki, Fumiyo
Hamada, Riku
Hamasaki, Yuko
Araki, Yoshinori
Gotoh, Yoshimitsu
Nakanishi, Koichi
Nakazato, Hitoshi
Matsuyama, Takeshi
Iijima, Kazumoto
Yoshikawa, Norishige
Ito, Shuichi
Honda, Masataka
Ishikura, Kenji
Funding for this research was provided by:
an endowed department sponsored by Asahi Kasei Pharma Corporation, Novartis Pharma K. K., Chugai Pharmaceutical Co., and Astellas Pharma
grants from Astellas Pharma, Daiichi Sankyo, and Zenyaku Kogyo
grants from Asahi Kasei Pharma Corporation, Astellas Pharma, Chugai Pharmaceutical Co., Japan Blood Products Organization, Pfizer, and Teijin
lecture and/or consulting fees from Asahi Kasei Pharma Corporation, Astellas Pharma, Chugai Pharmaceutical Co., Novartis Pharma K. K., and Zenyaku Kogyo
Article History
Received: 25 July 2021
Accepted: 10 November 2021
First Online: 2 December 2021
Competing interests
: S.Is., T.A., K.K., C.T., M.S., F.K., R.H., Y.A., Y.G., K.N., H.N., T.M., N.Y. and M.H. have no financial relationships relevant to this article to disclose. Y.H. belonged to an endowed department sponsored by Asahi Kasei Pharma Corporation, Novartis Pharma K. K., Chugai Pharmaceutical Co., and Astellas Pharma (until 28 February 2018). K.Ii. received grants from Astellas Pharma, Daiichi Sankyo, and Zenyaku Kogyo. S.It. received grants from Asahi Kasei Pharma Corporation, Astellas Pharma, Chugai Pharmaceutical Co., Japan Blood Products Organization, Pfizer, and Teijin; and lecture and/or consulting fees from Asahi Kasei Pharma Corporation, Astellas Pharma, Chugai Pharmaceutical Co., Novartis Pharma K. K., and Zenyaku Kogyo. K.Is. received grants from Astellas Pharma, Daiichi Sankyo, and Zenyaku Kogyo.